You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Ontology-Based Knowledge and Belief Management System

    SBC: INFOTECH SOFT, INC.            Topic: NIGMS

    DESCRIPTION provided by applicant Dramatic advances in the development of biomedical ontologies hold the promise of a deeper and clearer understanding of the molecular and genetic aspects that affect human health Biomedical data and knowledge stored in ontologies and databases have the potential to empower researchers in the life sciences to access and find conclusive evidence that can be translat ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A research and drug development tool for the real time in vitro study of single c

    SBC: KYTARO, INC.            Topic: 100

    DESCRIPTION In this SBIR Phase II PicoCal will develop a high throughput apparatus to measure changes in cell adhesion at the level of individual receptor ligand interactions in real time This tool finds critical applications in research and drug development and would allow researchers to study and manipulate adhesion by bioactive compounds to promote or inhibit physiological processes There is a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine

    SBC: NANOTHERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Noroviruses are a group of enteropathogenic viruses belonging to the taxonomic family Caliciviridae which causes approximately of epidemic non bacterial outbreaks of gastroenteritis around the world and may be responsible for of all foodborne outbreaks of gastroenteritis in the US In developing countries according to a estimate by CDC researchers up to children le ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Computational tools to analyze SNP data from patients with mental illness

    SBC: PARTEK, INC.            Topic: 101

    DESCRIPTION provided by applicant The broad long term objective of the proposed research is to develop and market a commercial software product that can be used to facilitate the analysis of genetic changes in order to elucidate chromosomal abnormalities that underlie diseases such as autism spectrum disorder bipolar disorder and schizophrenia Recent technological advances allow samples of ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    SBC: VASCULOX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 expression is thought to protect cancer cells from phagocytic clearance by sending a don't eat me signal to macrophages via SIRPa, an inhibitory receptor that prevents phagocytosis of CD47-bearing ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government